Namida Lab
Namida Lab is a Fayetteville, Arkansas-based biotechnology company developing tear-based proteomic diagnostic tests, serving individual consumers through its Auria at-home breast health assessment and clinicians through its Melody clinical screening product.
- Company typePrivate
- Founded2019
- HeadquartersFayetteville, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What Namida Lab does
Namida Lab, founded in 2019 and headquartered in Fayetteville, Arkansas, is a clinical-stage biotechnology company that has built a tear-based proteomic diagnostic platform for cancer screening. The core scientific thesis is that tears, unlike blood, lack large masking components such as albumin and hemoglobin, making small cancer-associated protein biomarkers easier to isolate and quantify. Namida operates a high-complexity CLIA-certified laboratory and has developed and validated an assay measuring two tear-based protein biomarkers associated with breast abnormalities, reporting 92% sensitivity and 58% specificity in work using 847 individually collected tear samples.
The company commercializes two product lines built on the same biomarker science: Auria, a direct-to-consumer at-home breast health assessment test sold through auria.care in the U.S. and Canada and eligible for FSA/HSA reimbursement, and Melody, a prescription-based clinical version targeted at healthcare providers. Auria+ is an add-on tier that bundles video consultations with Breast Health Educators. The diagnostic algorithm was developed using logistic regression on protein concentration data and was further refined through a partnership with Pattern Computer, whose Pattern Discovery Engine improved predictive accuracy and shortened development timelines. Namida also built a HIPAA-compliant iOS/Android consumer application with Helios Software to support clinical trial onboarding and consent.
Revenue mechanics combine one-time DTC kit sales, recurring CLIA-certified laboratory testing services, and (historically) transaction-fee COVID-19 antibody testing. The go-to-market is multi-channel: direct e-commerce to consumers, enterprise/B2B partnerships with breast centers and employers, event-driven clinical trial recruitment, and a series of research collaborations with high-profile clinical institutions including MD Anderson Cancer Center, UTMB, CARTI, Arkansas Urology, and Parkhill The Clinic for Women. Approximately $5.05M was raised in 2021; the team is roughly 10 people; Auria won the 2023 Edison Awards Top Intelligent Diagnostics Award. Active research now extends beyond breast cancer to ovarian, prostate, melanoma, pancreatic, and colon indications.
Namida Lab firmographics
Firmographics- Name
- Namida Lab
- Legal name
- Namida Lab, Inc.
- Website
- https://namidalab.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Namida Lab is a Fayetteville, Arkansas-based biotechnology company developing tear-based proteomic diagnostic tests, serving individual consumers through its Auria at-home breast health assessment and clinicians through its Melody clinical screening product.
- Ownership category
- akta.pro rank
Namida Lab industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
- akta.pro secondary industry
- Proteomics & Mass Spectrometry Services (HLAGANAB)
Keywords
Where Namida Lab is headquartered
LocationHeadquarters
- HQ city
- Fayetteville
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Namida Lab business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- At-home test kit sales: Direct-to-consumer sales of Auria breast health assessment test kits through auria.care website. Currently not covered by insurance but accepted with FSA/HSA accounts.
- Laboratory testing services: CLIA-certified lab processing of tear samples with provider-certified results delivered to consumers.
- COVID-19 antibody testing (historical): Serological antibody testing services primarily for employers and healthcare workers during the pandemic.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Auria at-home breast health assessment test |
| Unit Pricing | Pay-as-you-go | COVID-19 antibody test (general public) |
| Unit Pricing | Pay-as-you-go | COVID-19 antibody test (healthcare workers, first responders, educators) |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Namida Lab product offering
Product offeringCore offering
Namida Lab develops tear-based proteomic diagnostic tests for cancer screening. Its flagship products include Auria, an at-home breast health assessment test sold direct-to-consumer, and Melody, a prescription-based tear-derived breast cancer screening test for clinical settings. Both products analyze protein biomarkers in tear fluid to detect breast abnormalities, processed through the company's CLIA-certified laboratory in Fayetteville, Arkansas.
Product overview
Namida Lab offers two related tear-based breast cancer screening products: Auria™ (direct-to-consumer) and Melody® (prescription/clinical). Auria™ is an at-home breast health assessment that women can purchase online, while Melody® is available through healthcare providers. Both products analyze protein biomarkers in tears to detect breast abnormalities. Auria+ adds consultation services with Breast Health Educators to the base Auria offering. The company operates a CLIA-certified laboratory to process tear samples and deliver results.
Differentiator
Problem solved
Functional benefit
Brands
- Auria: At-home breast health assessment test powered by tears for early detection of breast cancer risk
- Melody
Products and services
- Auria An at-home breast health assessment test that uses protein biomarkers found in tears to detect potential breast abnormalities. The non-invasive test provides personalized results and recommendations for women ages 30 and over, designed to supplement routine mammogram screening. Available in the U.S. and Canada.
- Auria+
- Melody Prescription-based tear-derived breast cancer screening test designed for use in clinical settings. The lab-developed test analyzes protein biomarkers from tears to assess breast cancer risk and is intended to supplement routine screening mammography.
- COVID-19 Antibody Test Serological COVID-19 antibody testing services offered primarily to employers and healthcare workers during the pandemic. Priced at $99 for general public and $69 for healthcare workers, first responders, and educators.
Quantifiable outcome
- 92% sensitivity for breast cancer detection
- +4 more outcomes
Companies that use Namida Lab
Customer profileNamed customers7 records
Segments1 record
Ideal customer profiles3 records
Namida Lab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Namida Lab partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core, major and minor.
- Healthyr PartnerscoreStrategic partnership to expand early breast cancer detection through Auria at-home breast health assessment, empowering women and encouraging early detection.
- American Cancer Society National Breast Cancer RoundtablemajorNamida joined ACS National Breast Cancer Roundtable to contribute to national breast cancer early detection initiatives.
- Clinton Global Initiative (CGI) GreenhousemajorNamida attended CGI Greenhouse 2023 meeting as part of commitment to global health initiatives.
- University of Texas Medical Branch (UTMB)core12-week clinical research study on Melody tear-based breast cancer screening test with recently diagnosed breast cancer patients not yet in treatment. Dr. Suzanne Klimberg serving as principal investigator.
- Parkhill The Clinic for WomencoreRecruitment site for clinical trials around Melody for dense breast tissue application. Dr.s Robert Hix and Paige Partridge recruiting patients.
- Arkansas UrologycorePartnership for prostate cancer screening study collecting tear samples to identify proteins that could lead to early cancer detection test for prostate cancer.
- CARTIcore10-month study collecting tear samples from cancer patients diagnosed with breast, ovarian, prostate, melanoma, pancreatic, or colon cancer. CARTI has 18 treatment locations in 15 Arkansas communities.
- MD Anderson Cancer CentermajorClinical study for women with dense breast tissue evaluating Melody tear-based screening as supplemental tool to mammography. 100 women enrolled over 6 months.
- Pattern ComputercoreAI partnership applying Pattern Discovery Engine to Namida Lab data resulting in significant improvement to predictive accuracy for breast cancer screening and accelerated development timeline.
- Helios SoftwarecoreBoston-based health IT partnership to build HIPAA-compliant consumer app for clinical trial onboarding, consent, and health information collection available on iOS and Android.
- Community ClinicminorPartnership for study of breast cancer screening test with community clinic in Arkansas.
- Heartland PharmacyminorPharmacy partnership for COVID-19 antibody testing collection at Fayetteville and Rogers locations, expanded to Central Arkansas and River Valley.
- Heights Corner MarketminorLittle Rock retail location for COVID-19 antibody testing services, adjacent to Heights Corner Market on Kavanaugh Blvd.
- Dickson Street ClinicminorDowntown Fayetteville family medicine clinic partnership for COVID-19 antibody testing collection services.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Namida Lab competitors and assessment
Company assessmentDirect peers
- GRAIL: Developer of Galleri, a multi-cancer early-detection blood test. GRAIL is the closest analog to Namida's cancer-screening thesis: a novel-sample (blood vs. tears), non-imaging, early-detection screening test positioned for asymptomatic adults, with an identical regulatory and adoption pathway.
- LetsGetChecked: At-home diagnostics company offering lab-based health and cancer screening kits via DTC e-commerce. Comparable sample collection, lab processing, and consumer health GTM.
- Everlywell: Direct-to-consumer at-home diagnostics platform selling lab-based test kits online (FSA/HSA, no insurance). Most directly comparable to Auria's GTM motion, fulfillment model, and consumer-pay positioning.
Broad incumbents
- Exact Sciences: Public diagnostics company behind Cologuard (CRC screening) and the Oncotype DX franchise. Comparable as a stool/blood-based cancer screening platform that built direct-to-consumer, employer, and provider channels — directly relevant to Namida's commercial playbook.
- Hologic: Dominant mammography and women's health diagnostics incumbent. Auria is explicitly positioned as a supplemental tool to mammography, making Hologic the primary incumbent whose installed base and clinical relationships Auria must coexist with in breast centers.
- Myriad Genetics: Established molecular diagnostics company with breast cancer risk tests (BRACAnalysis, RiskScore). Comparable as an incumbent genetic/molecular diagnostics franchise in breast cancer risk assessment that Auria could partner with or compete against on clinical-channel access.
Emerging players
- BillionToOne: Molecular diagnostics company using novel assay approaches (e.g., UNITY fetal screen, Northstar liquid biopsy). Comparable as a small, science-driven specialty lab using novel sample/assay chemistry to enter mainstream screening.
- Natera: Cell-free DNA-based oncology and reproductive health testing company. Comparable as a blood-based molecular diagnostics platform pursuing multi-cancer screening applications and similar specialty-lab business model.
- Color Health: Population-scale genetic testing and cancer screening company with employer and health system channels. Comparable as a specialty lab offering cancer-risk screening with similar B2B enterprise motion.
- Volpara Health: Breast density analytics and supplemental screening software for mammography. Highly comparable as a breast-screening adjunct focused on dense-breast tissue, the same unmet need Auria targets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Namida Lab social profiles
Digital presenceNamida Lab compliance and trust
Trust signalCompliance1 record
Namida Lab financial estimates
Financial estimateRevenue estimate
Valuation estimate
Namida Lab leadership team
Management profileNumber of profiles
Profiles5 records
Namida Lab funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Namida Lab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Namida Lab
What does Namida Lab do?
Namida Lab develops tear-based proteomic diagnostic tests for cancer screening. Its flagship products include Auria, an at-home breast health assessment test sold direct-to-consumer, and Melody, a prescription-based tear-derived breast cancer screening test for clinical settings. Both products analyze protein biomarkers in tear fluid to detect breast abnormalities, processed through the company's CLIA-certified laboratory in Fayetteville, Arkansas.
Is Namida Lab a public or private company?
Namida Lab is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Namida Lab founded?
Namida Lab was founded in 2019. It employs 1 to 10 people.
Where is Namida Lab based?
Namida Lab is headquartered in Fayetteville, United States, in the North America region.
How does Namida Lab make money?
Three revenue lines are on record. At-home test kit sales are the primary driver. The others are laboratory testing services and COVID-19 antibody testing (historical).
Who are Namida Lab's main competitors?
Direct peers on record are GRAIL, LetsGetChecked and Everlywell. Broad incumbents are Exact Sciences, Hologic and Myriad Genetics. Emerging players are BillionToOne, Natera, Color Health and Volpara Health.
Does Namida Lab have an API?
No public API is recorded for Namida Lab.
What industry is Namida Lab in?
Namida Lab's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 621511 and its SIC code is 8071.